Ultragenyx Q4 revenue rises 25% amid restructuring

Reuters

Feb 13

Ultragenyx Q4 revenue rises 25% amid restructuring

Overview

Biopharmaceutical firm's Q4 2025 revenue grew 25% yr/yr
Company initiated a strategic restructuring plan, reducing headcount by 10%
2026 revenue expected to rise 8% to 13% from 2025

Outlook

Ultragenyx expects 2026 revenue between $730 mln and $760 mln
Company aims for profitability in 2027 through strategic restructuring

Result Drivers

CRYSVITA GROWTH - Crysvita revenue grew 17% in 2025, driven by strong sales in Latin America and Türkiye
EVKEEZA DEMAND - Evkeeza revenue rose 84% in 2025, reflecting increased demand following international launches

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q4 EPS		-$1.29
Q4 Net Income		-$129 mln
Q4 Operating Expenses		$321 mln

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 20 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Ultragenyx Pharmaceutical Inc is $61.50, about 157.5% above its February 11 closing price of $23.88

Press Release: ID:nGNX88ZDMT

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2611397057"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2611397057\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2611397057?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-13 05:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2611397057","market":"us","top_or_hot":-1,"title":"Ultragenyx Q4 revenue rises 25% amid restructuring","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Ultragenyx Q4 revenue rises 25% amid restructuring</title></head><body><p><span>Overview</span></p><ul><li><p>Biopharmaceutical firm's Q4 2025 revenue grew 25% yr/yr</p></li><li><p>Company initiated a strategic restructuring plan, reducing headcount by 10%</p></li><li><p>2026 revenue expected to rise 8% to 13% from 2025</p></li></ul><p><span>Outlook</span></p><ul><li><p>Ultragenyx expects 2026 revenue between $730 mln and $760 mln</p></li><li><p>Company aims for profitability in 2027 through strategic restructuring</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>CRYSVITA GROWTH - Crysvita revenue grew 17% in 2025, driven by strong sales in Latin America and Türkiye</p></li><li><p>EVKEEZA DEMAND - Evkeeza revenue rose 84% in 2025, reflecting increased demand following international launches</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q4 EPS</p></td><td></td><td><p>-$1.29</p></td><td></td></tr><tr><td><p>Q4 Net Income</p></td><td></td><td><p>-$129 mln</p></td><td></td></tr><tr><td><p>Q4 Operating Expenses</p></td><td></td><td><p>$321 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 20 \"strong buy\" or \"buy\", 1 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the pharmaceuticals peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for <a href=\"https://laohu8.com/S/RARE\">Ultragenyx Pharmaceutical Inc</a> is $61.50, about 157.5% above its February 11 closing price of $23.88</p></li></ul><p>Press Release: <span>ID:nGNX88ZDMT</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ultragenyx Q4 revenue rises 25% amid restructuring</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUltragenyx Q4 revenue rises 25% amid restructuring\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-13 05:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Ultragenyx Q4 revenue rises 25% amid restructuring</title></head><body><p><span>Overview</span></p><ul><li><p>Biopharmaceutical firm's Q4 2025 revenue grew 25% yr/yr</p></li><li><p>Company initiated a strategic restructuring plan, reducing headcount by 10%</p></li><li><p>2026 revenue expected to rise 8% to 13% from 2025</p></li></ul><p><span>Outlook</span></p><ul><li><p>Ultragenyx expects 2026 revenue between $730 mln and $760 mln</p></li><li><p>Company aims for profitability in 2027 through strategic restructuring</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>CRYSVITA GROWTH - Crysvita revenue grew 17% in 2025, driven by strong sales in Latin America and Türkiye</p></li><li><p>EVKEEZA DEMAND - Evkeeza revenue rose 84% in 2025, reflecting increased demand following international launches</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q4 EPS</p></td><td></td><td><p>-$1.29</p></td><td></td></tr><tr><td><p>Q4 Net Income</p></td><td></td><td><p>-$129 mln</p></td><td></td></tr><tr><td><p>Q4 Operating Expenses</p></td><td></td><td><p>$321 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 20 \"strong buy\" or \"buy\", 1 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the pharmaceuticals peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for <a href=\"https://laohu8.com/S/RARE\">Ultragenyx Pharmaceutical Inc</a> is $61.50, about 157.5% above its February 11 closing price of $23.88</p></li></ul><p>Press Release: <span>ID:nGNX88ZDMT</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RARE","symbol_name":"Ultragenyx Pharmaceutical Inc","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260212:nL1N3Z81F9:1","article_id":"2611397057","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2611397057","pubTimestamp":1770930611,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Ultragenyx Q4 revenue rises 25% amid restructuringOverviewBiopharmaceutical firm's Q4 2025 revenue grew 25% yr/yrCompany initiated a strategic restructuring plan, reducing headcount by 10%2026 revenue","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RARE":"Ultragenyx Pharmaceutical Inc","BK4139":"生物科技"},"translate_title":"Ultragenyx第四季度收入在重组中增长25%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RARE":0.9},"content_text":"Ultragenyx Q4 revenue rises 25% amid restructuringOverviewBiopharmaceutical firm's Q4 2025 revenue grew 25% yr/yrCompany initiated a strategic restructuring plan, reducing headcount by 10%2026 revenue expected to rise 8% to 13% from 2025OutlookUltragenyx expects 2026 revenue between $730 mln and $760 mlnCompany aims for profitability in 2027 through strategic restructuringResult DriversCRYSVITA GROWTH - Crysvita revenue grew 17% in 2025, driven by strong sales in Latin America and TürkiyeEVKEEZA DEMAND - Evkeeza revenue rose 84% in 2025, reflecting increased demand following international launchesKey DetailsMetricBeat/MissActualConsensus EstimateQ4 EPS-$1.29Q4 Net Income-$129 mlnQ4 Operating Expenses$321 mlnAnalyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 20 \"strong buy\" or \"buy\", 1 \"hold\" and no \"sell\" or \"strong sell\"The average consensus recommendation for the pharmaceuticals peer group is \"buy\"Wall Street's median 12-month price target for Ultragenyx Pharmaceutical Inc is $61.50, about 157.5% above its February 11 closing price of $23.88Press Release: ID:nGNX88ZDMTFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}